Status:
COMPLETED
Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea
Lead Sponsor:
Celgene
Conditions:
Multiple Myeloma
Eligibility:
All Genders
19+ years
Brief Summary
PMS period: 09Jun2017 \~ 08Jun2023 Target no.: 600patients indication: POMALYST in combination with dexamethasone is indicated in the treatment of patients with relapsed and refractory multiple myelo...
Eligibility Criteria
Inclusion
- The main criteria for inclusion of this DUE is the same as the approved package insert of POMALYST® in Korea. Based on the current PI, patients who are treated with POMALYST® based on the following criteria, can be registered into this DUE.
- POMALYST® in combination with dexamethasone is indicated in the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib.
- The actual inclusion criteria and patient population who can start with POMALYST® treatment will be narrowed down according to the local health insurance reimbursement condition.
Exclusion
- There's no exclusion criteria
Key Trial Info
Start Date :
December 28 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 16 2023
Estimated Enrollment :
397 Patients enrolled
Trial Details
Trial ID
NCT03288974
Start Date
December 28 2017
End Date
November 16 2023
Last Update
April 15 2025
Active Locations (33)
Enter a location and click search to find clinical trials sorted by distance.
1
Korea University Ansan Hospital
Ansan, South Korea, 15355
2
Hallym University Sacred Heart Hospital
Anyang, South Korea, 14068
3
Soonchunhyang University Hospital
Bucheon-si, South Korea, 14584
4
Inje University Busan Paik Hospital
Busan, South Korea, 47932